Last reviewed · How we verify
Tetra Discovery Partners — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Zatolmilast/ BPN14770 | Zatolmilast/ BPN14770 | phase 3 | ||||
| BPN14770/ zatolmilast | BPN14770/ zatolmilast | phase 3 | Phosphodiesterase 4D (PDE4D) inhibitor | PDE4D | Neurology |
Therapeutic area mix
- Autoimmune diseases · 1
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AmMax Bio, Inc. · 1 shared drug class
- Aronora, Inc. · 1 shared drug class
- Astellas Pharma Europe B.V. · 1 shared drug class
- Astellas Pharma Global Development, Inc. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Axikin Pharmaceuticals, Inc. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Tetra Discovery Partners:
- Tetra Discovery Partners pipeline updates — RSS
- Tetra Discovery Partners pipeline updates — Atom
- Tetra Discovery Partners pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Tetra Discovery Partners — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tetra-discovery-partners. Accessed 2026-05-16.